Influenza

Journal of Pharmacology And Experimental Therapeutics Fast Forward 
First published on August 28, 2007; DOI: 10.1124/jpet.107.124719


0022-3565/07/3232-675-683$20.00
JPET 323:675-683, 2007


INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Modulation of Airway Responses to Influenza A/PR/8/34 by Delta9-Tetrahydrocannabinol in C57BL/6 Mice

John P. BuchweitzPeer W. F. KarmausJack R. HarkemaKurt J. Williams, and Norbert E. Kaminski

Departments of Pharmacology and Toxicology (J.P.B., N.E.K) and Pathobiology and Diagnostic Investigation (J.R.H., K.J.W.) and Center for Integrative Toxicology (J.P.B., P.W.F.K., J.R.H, N.E.K.), Michigan State University, East Lansing, Michigan

Delta9-Tetrahydrocannabinol (Delta9-THC) has been widely established as a modulator of host immune responses. Accordingly, the objective of the present study was to examine the effects of Delta9-THC on the immune response within the lungs and associated changes in the morphology of the bronchiolar epithelium after one challenge with a nonlethal dose of the influenza virus A/PR/8 (PR8). C57BL/6 mice were treated by oral gavage with Delta9-THC and/or vehicle (corn oil) for 5 consecutive days. On day 3, mice were instilled intranasally with 50 plaque-forming units of PR8 and/or vehicle (saline) 4 h before Delta9-THC exposure. Mice were subsequently killed 7 and 10 days postinfection (dpi). Viral hemagglutinin 1 (H1) mRNA levels in the lungs were increased in a dose-dependent manner with Delta9-THC treatment. Enumeration of inflammatory cell types in bronchoalveolar lavage fluid showed an attenuation of macrophages and CD4+ and CD8+ T cells in Delta9-THC-treated mice compared with controls. Likewise, the magnitude of inflammation and virus-induced mucous cell metaplasia, as assessed by histopathology, was reduced in Delta9-THC-treated mice by 10 dpi. Collectively, these results suggest that Delta9-THC treatment increased viral load, as assessed by H1 mRNA levels, through a decrease in recruitment of macrophages and lymphocytes, particularly CD4+ and CD8+ T cells, to the lung.


Received April 20, 2007; accepted August 27, 2007.

Address correspondence to: Dr. Norbert E. Kaminski, 315 National Food Safety and Toxicology Building, Michigan State University, East Lansing, MI 48824-1317. E-mail address: kamins11@msu.edu